Andere Kunden interessierten sich auch für
![Formulation, Development, And In-vivo Studies Of Anti-hiv Vaginal Film]( "Formulation, Development, And In-vivo Studies Of Anti-hiv Vaginal Film")
Formulation, Development, And In-vivo Studies Of Anti-hiv Vaginal Film26,99 €![Potential HIV Reverse Transcriptase Inhibitors]( "Potential HIV Reverse Transcriptase Inhibitors")
Potential HIV Reverse Transcriptase Inhibitors32,99 €![Adverse Drug Reactions To Highly Active Antiretroviral Therapy (HAART)]( "Adverse Drug Reactions To Highly Active Antiretroviral Therapy (HAART)")
Adverse Drug Reactions To Highly Active Antiretroviral Therapy (HAART)32,99 €![Drug Addiction and AIDS]( "Drug Addiction and AIDS")
Drug Addiction and AIDS40,99 €![Entry Inhibitors in HIV Therapy]( "Entry Inhibitors in HIV Therapy")
Entry Inhibitors in HIV Therapy110,99 €![Ritonavir]( "Ritonavir")
Ritonavir32,99 €![Adesão à terapêutica antirretroviral por indivíduos com HIV/AIDS]( "Adesão à terapêutica antirretroviral por indivíduos com HIV/AIDS")
Adesão à terapêutica antirretroviral por indivíduos com HIV/AIDS23,99 €
There are the two type of HIV mainly they are HIV-1 and HIV-2. HIV-2 is less pathogenic and less transmissible compared to HIV-1. This is believed to be due to the lower viral load that is seen in HIV-2 infected patients. genetic variation and evolution in the pol gene was studied, with special interests in resistance-associated mutations in HIV-2 infected patients failing antiretroviral treatment. There is observation in some mutations known to cause resistance in HIV-1 such as M184V, Q151M and E219D; but most resistance mutations appeared to differ from what is known in HIV-1. The main conclusion from this work is that specific algorithms for HIV-2 resistance interpretation are needed, because the algorithms for HIV-1 cannot be used. They were studied the evolution of co-receptor usage, neutralization escape and env gene sequence. It is reported that a switch from CCR5 to CXCR4 using virus during disease progression. They did not see a clear pattern of neutralization escape as is seen in HIV-1. A pattern of changes in the number of potential N-linked glycosylation sites during disease progression has been observed. HIV-2 has fewer potential N-linked glycosylation sites in V3.